New Article Latest Procrit Drug Warning
On November 30, 2006, reports came out that two studies in this month’s New England Journal of Medicine have called into question the overuse of drugs in the treatment of anemia in kidney patients. Johnson & Johnson’s Procrit and Amgen’s Epogen are the two most popular anemia drugs which are at the center of the controversy, as researchers try to determine whether they’ve been over-prescribed by medical professionals. Sales of anemia drugs are nearing $10 billion annually. Procrit (Generic: Epoetin alfa) was granted approval in 1999 by the FDA.
According to the above studies, Scientists established that anemic kidney patients are susceptible to heart problems or death when aggressively treated with Epogen or other anemia drugs. The drugs are intended to boost hemoglobin in anemic patients, but the increase in hemoglobin is apparently associated with other serious risks. Prior to the arrival of these anemia treatments, patients had to undergo transfusions to keep their red blood cell counts at healthy levels.
These new drugs have been very successful in boosting red blood cell counts, but the fear today is that doctors have become too reliant on the drugs and that they aren’t sufficiently aware of the risks related to boosting hemoglobin (a main component of red blood cells) in kidney patients, which can include heart attack, stroke, and high blood pressure.
Legal help for Procrit Users
If you or a loved has taken Procrit and suffered heart problems or death, please fill out the form at the right for a free case evaluation by a qualified defective drugs attorney or call us at 1-800-YOURLAWYER (1-800-968-7529).